AxoGen (LT3) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

LT3 Analyst Ratings

Strong Buy

8 Buy

0 Hold

0 Sell

Based on 8 analysts giving stock ratings to

AxoGen

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

LT3 Stock 12 Month Forecast

Average Price Target

€43.86

▲(41.29% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for AxoGen in the last 3 months. The average price target is €43.86 with a high forecast of €48.12 and a low forecast of €42.00. The average price target represents a 41.29% change from the last price of €31.04.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"€8","49":"€49","18.25":"€18.25","28.5":"€28.5","38.75":"€38.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":48.1211324,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€48.12</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":43.85585021,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€43.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41.99662464,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€42.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,18.25,28.5,38.75,49],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.6,40.25547172307692,40.910943446153844,41.56641516923077,42.221886892307694,42.877358615384615,43.53283033846154,44.188302061538465,44.84377378461539,45.49924550769231,46.15471723076923,46.81018895384616,47.46566067692308,{"y":48.1211324,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.6,39.92737309307692,40.254746186153845,40.58211927923077,40.909492372307696,41.23686546538462,41.56423855846154,41.89161165153846,42.21898474461538,42.546357837692305,42.873730930769234,43.201104023846156,43.52847711692308,{"y":43.85585021,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.6,39.78435574153846,39.96871148307692,40.153067224615384,40.337422966153845,40.521778707692306,40.70613444923077,40.890490190769235,41.074845932307696,41.25920167384616,41.44355741538462,41.62791315692308,41.81226889846154,{"y":41.99662464,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.05,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.6,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.9,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.4,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.84,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.17,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.6,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€48.12

Average Price Target€43.86

Lowest Price Target€42.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Michael Sarcone

Jefferies

€43.75

Buy

40.94%

Upside

Reiterated

07/06/26

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (NASDAQ: RVMD), AxoGen (NASDAQ: AXGN) and Eli Lilly & Co (NYSE: LLY)

Caitlin Roberts

Canaccord Genuity

€43.75

Buy

40.94%

Upside

Reiterated

05/04/26

Canaccord Genuity Sticks to Its Buy Rating for AxoGen (AXGN)

Jayson Bedford

Raymond James

€35.87→€42

Buy

35.30%

Upside

Reiterated

04/29/26

AxoGen price target raised to $48 from $41 at Raymond JamesAxoGen price target raised to $48 from $41 at Raymond James

Anthony Petrone

Mizuho Securities

€35→€48.12

Buy

55.03%

Upside

Reiterated

04/29/26

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), AxoGen (NASDAQ: AXGN) and Niagen Bioscience (NASDAQ: NAGE)

Yi Chen

H.C. Wainwright

€34.12→€43.75

Buy

40.94%

Upside

Reiterated

04/29/26

AxoGen price target raised to $50 from $39 at H.C. WainwrightAxoGen price target raised to $50 from $39 at H.C. Wainwright

Larry Biegelsen

Wells Fargo

€35→€42

Buy

35.30%

Upside

Reiterated

04/29/26

Analysts' Top Healthcare Picks: Spyre Therapeutics (SYRE), AxoGen (AXGN)

David Turkaly

Citizens JMP

€36.75→€43.75

Buy

40.94%

Upside

Reiterated

04/29/26

AxoGen price target raised to $50 from $42 at CitizensAxoGen price target raised to $50 from $42 at Citizens

Frank Takkinen

Lake Street

€43.75

Buy

40.94%

Upside

Reiterated

04/28/26

Lake Street Keeps Their Buy Rating on AxoGen (AXGN)

Mike Kratky

Leerink Partners

€19.25

Buy

-37.99%

Downside

Reiterated

08/25/25

Optimistic Buy Rating for AxoGen Amid Regulatory Delays and Market Potential

Ross Osborn

Cantor Fitzgerald

€20.12→€22.75

Buy

-26.71%

Downside

Reiterated

08/11/25

Cantor Fitzgerald Reaffirms Their Buy Rating on AxoGen (AXGN)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Michael Sarcone

Jefferies

€43.75

Buy

40.94%

Upside

Reiterated

07/06/26

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (NASDAQ: RVMD), AxoGen (NASDAQ: AXGN) and Eli Lilly & Co (NYSE: LLY)

Caitlin Roberts

Canaccord Genuity

€43.75

Buy

40.94%

Upside

Reiterated

05/04/26

Canaccord Genuity Sticks to Its Buy Rating for AxoGen (AXGN)

Jayson Bedford

Raymond James

€35.87→€42

Buy

35.30%

Upside

Reiterated

04/29/26

AxoGen price target raised to $48 from $41 at Raymond JamesAxoGen price target raised to $48 from $41 at Raymond James

Anthony Petrone

Mizuho Securities

€35→€48.12

Buy

55.03%

Upside

Reiterated

04/29/26

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), AxoGen (NASDAQ: AXGN) and Niagen Bioscience (NASDAQ: NAGE)

Yi Chen

H.C. Wainwright

€34.12→€43.75

Buy

40.94%

Upside

Reiterated

04/29/26

AxoGen price target raised to $50 from $39 at H.C. WainwrightAxoGen price target raised to $50 from $39 at H.C. Wainwright

Larry Biegelsen

Wells Fargo

€35→€42

Buy

35.30%

Upside

Reiterated

04/29/26

Analysts' Top Healthcare Picks: Spyre Therapeutics (SYRE), AxoGen (AXGN)

David Turkaly

Citizens JMP

€36.75→€43.75

Buy

40.94%

Upside

Reiterated

04/29/26

AxoGen price target raised to $50 from $42 at CitizensAxoGen price target raised to $50 from $42 at Citizens

Frank Takkinen

Lake Street

€43.75

Buy

40.94%

Upside

Reiterated

04/28/26

Lake Street Keeps Their Buy Rating on AxoGen (AXGN)

Mike Kratky

Leerink Partners

€19.25

Buy

-37.99%

Downside

Reiterated

08/25/25

Optimistic Buy Rating for AxoGen Amid Regulatory Delays and Market Potential

Ross Osborn

Cantor Fitzgerald

€20.12→€22.75

Buy

-26.71%

Downside

Reiterated

08/11/25

Cantor Fitzgerald Reaffirms Their Buy Rating on AxoGen (AXGN)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

BBOTBridgeBio Oncology Therapeutics

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AxoGen

3 Months

Frank TakkinenLake Street

Success Rate

7/9 ratings generated profit

Average Return

+19.52%

Copying Frank Takkinen's trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +19.52% per trade.

1 Year

Mike KratkyLeerink Partners

Success Rate

13/13 ratings generated profit

Average Return

+147.28%

Copying Mike Kratky's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +147.28% per trade.

2 Years

Mike KratkyLeerink Partners

Success Rate

13/13 ratings generated profit

Average Return

+283.04%

Copying Mike Kratky's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +283.04% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LT3 Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, LT3 has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. LT3 average Analyst price target in the past 3 months is 43.86.

Each month's total comprises the sum of three months' worth of ratings.

LT3 Financial Forecast

LT3 Earnings Forecast

Next quarter’s earnings estimate for LT3 is €0.10 with a range of €0.07 to €0.13. The previous quarter’s EPS was €0.06. LT3 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year LT3 has Performed in-line its overall industry.

LT3 Sales Forecast

Next quarter’s sales forecast for LT3 is €58.77M with a range of €57.80M to €59.55M. The previous quarter’s sales results were €53.82M. LT3 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year LT3 has Performed in-line its overall industry.

LT3 Stock Forecast FAQ

What is DE:LT3’s average 12-month price target, according to analysts?

Based on analyst ratings, AxoGen’s 12-month average price target is 43.86.

What is DE:LT3’s upside potential, based on the analysts’ average price target?

AxoGen has 41.29% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AxoGen a Buy, Sell or Hold?

AxoGen has a consensus rating of Strong Buy, which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.

What is AxoGen’s share price target?

The average share price target for AxoGen is 43.86. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €48.12 ,and the lowest forecast is €42.00. The average share price target represents 41.29% Increase from the current price of €31.04.

What do analysts say about AxoGen?

AxoGen’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of AxoGen?

To buy shares of DE:LT3, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

AxoGen (LT3) Stock Forecast & Price Target

LT3 Analyst Ratings

LT3 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering AxoGen

LT3 Analyst Recommendation Trends

LT3 Financial Forecast

LT3 Earnings Forecast

LT3 Sales Forecast

LT3 Stock Forecast FAQ

Detailed List of Analyst Forecasts